BioDelivery Sciences enters patent settlement on Bunavail

12 October 2017

Shares of specialty pharma firm BioDelivery Sciences International (Nasdaq: BDSI) were up 4.58% at $3.08 mid-morning, after it announced that it has entered into a Settlement Agreement over its opioid dependence treatment.

The settlement resolves BDSI's previously-reported Bunavail (buprenorphine and naloxone) buccal film, patent litigation against Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA), its US subsidiary and Actavis Laboratories pending in the US District Court for the District of Delaware.

BDSI alleged in the lawsuits that the generic form of Bunavail buccal film, which Teva is seeking approval to market in the USA under to two Abbreviated New Drug Application (ANDA) filings with the US Food and Drug Administration, infringed upon several US patents owned by BDSI.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK